Accolade Moves Higher But Growth Is Slowing

Published by
ValueWalk

Accolade (NASDAQ:ACCD) is certainly an interesting play on the health care space providing business and employee services geared toward helping clients navigate the cumbersome health benefits arena. The pandemic helped boost the company’s business and has on track to continue growing but there is a fly in the ointment. Not only is the revenue growth slowing but it is expected to slow further in the coming quarter and for the full year and, worse, profitability remains elusive. The company CEO is optimistic profitability will be reached by their 2025 target but we think that’s a long way off an…

Read More

See also  Every Chicago Bulls player who won NBA title alongside Michael Jordan

Leave a Reply